Inhibikase Therapeutics, Inc. (IKT)
| Market Cap | 215.02M |
| Revenue (ttm) | 1 |
| Net Income (ttm) | -19.57M |
| Shares Out | 67.19M |
| EPS (ttm) | -2.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,799,870 |
| Open | 3.130 |
| Previous Close | 3.160 |
| Day's Range | 3.070 - 3.500 |
| 52-Week Range | 1.120 - 4.200 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+103.13%) |
| Earnings Date | Nov 14, 2024 |
About IKT
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collab... [Read more]
Financial Performance
In 2023, Inhibikase Therapeutics's revenue was $260,501, an increase of 111.03% compared to the previous year's $123,440. Losses were -$19.03 million, 5.40% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IKT stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 103.13% from the latest price.
News
Inhibikase: Potential To Improve Current Treatment Options For PAH Patients
The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims ...
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hyp...
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 ...
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeuti...
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET Company Participants Alexander Lobo - Precision AQ, Investor Relations Milton Werner - President...
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibit...
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibit...
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (In...
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibito...
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe...
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibito...
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension –
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonar...
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibi...
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate Company to pursue eleven indications for IkT-001Pro; all previously approved for treat...
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson's disease - - The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Park...
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibit...
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-Pr...
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications -
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q3 2023 Earnings Conference Call November 15, 2023 8:00 AM ET Company Participants Alex Lobo - IR Milton Werner - CEO Joseph Frattaroli - CFO Conference Cal...